Cargando…
Absent and abundant MET immunoreactivity is associated with poor prognosis of patients with oral and oropharyngeal squamous cell carcinoma
Although the receptor tyrosine kinase (RTK) MET is widely expressed in head and neck squamous cell carcinoma (HNSCC), its prognostic value remains unclear. This might be due to the use of a variety of antibodies and scoring systems. Here, the reliability of five commercial C-terminal MET antibodies...
Autores principales: | De Herdt, Maria J., Willems, Stefan M., van der Steen, Berdine, Noorlag, Rob, Verhoef, Esther I., van Leenders, Geert J.L.H., van Es, Robert J.J., Koljenović, Senada, de Jong, Robert J. Baatenburg, Looijenga, Leendert H.J. |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Impact Journals LLC
2016
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4914349/ https://www.ncbi.nlm.nih.gov/pubmed/26909606 http://dx.doi.org/10.18632/oncotarget.7534 |
Ejemplares similares
-
The Potential of MET Immunoreactivity for Prediction of Lymph Node Metastasis in Early Oral Tongue Squamous Cell Carcinoma
por: De Herdt, Maria J., et al.
Publicado: (2021) -
The Occurrence of MET Ectodomain Shedding in Oral Cancer and Its Potential Impact on the Use of Targeted Therapies
por: De Herdt, Maria J., et al.
Publicado: (2022) -
MET expression during prostate cancer progression
por: Verhoef, Esther I., et al.
Publicado: (2016) -
Clinical relevance of copy number profiling in oral and oropharyngeal squamous cell carcinoma
por: van Kempen, Pauline M W, et al.
Publicado: (2015) -
The unveiled reality of human papillomavirus as risk factor for oral cavity squamous cell carcinoma
por: Nauta, Irene H., et al.
Publicado: (2021)